Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06491550 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
A Phase 1 study of Healthy Participants, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
- 2
- Study locations
NCT06491550 is a Phase 1 study of Healthy Participants that has completed, run by AstraZeneca. The registered enrollment target is 91 participants, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (40% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT06491550, a Phase 1 study of Healthy Participants, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study consists of 3 parts: Part A, Part B and Part C. This study will compare the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD4144 with placebo in healthy participants, in Part A and Part B. Part C of this study will investigate the possibility of drug-drug interaction (DDI) between IV AZD4144 and oral rosuvastatin and furosemide by evaluating the PK of rosuvastatin and furosemide when administered alone and in combination with single IV dose of AZD4144
Conditions Studied
Interventions
- DRUG AZD4144- Part A
- DRUG Placebo- Part A
- DRUG AZD4144- Part B
- DRUG Placebo- Part B
- DRUG Rosuvastatin and Furosemide- Part C
Study Locations (2)
California
- Research Site - Glendale
Maryland
- Research Site - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2024-07-15 |
| Est. Completion | 2025-06-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06491550
The ClinicalTrials.gov registry entry for NCT06491550 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (40% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Participants appearing as the primary indexed condition, and to 5 interventions - of which AZD4144- Part A is the first listed.
NCT06491550 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Maryland.
Frequently Asked Questions
What is clinical trial NCT06491550 about?
NCT06491550 is a clinical study titled "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants". This study consists of 3 parts: Part A, Part B and Part C. This study will compare the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of AZD4144 with placebo in healthy participants, in Part A and Part B. Part C of this study will investigate the possibility of drug-drug inte...
What is the current status of trial NCT06491550?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2024-07-15. Estimated completion is 2025-06-11.
What conditions does trial NCT06491550 study?
This clinical trial studies the following conditions: Healthy Participants.
What interventions are being tested in trial NCT06491550?
The interventions under investigation include: AZD4144- Part A (DRUG), Placebo- Part A (DRUG), AZD4144- Part B (DRUG), Placebo- Part B (DRUG), Rosuvastatin and Furosemide- Part C (DRUG).
Who is sponsoring clinical trial NCT06491550?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06491550 being conducted?
This trial has 2 study locations across California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
RECRUITING · Phase 1
-
A Study to Learn About a Vaccine Against E Coli in Healthy Adults
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.